Natural protein A is a chemical component derived from bacterial cell of staphylococcus aureus species. In the biotechnology sector, the product is mainly used in purification of monoclonal antibodies in large scale industries.
The global protein A resin market is estimated to account for US$ 511.7 Mn in terms of value in 2020 and is expected to reach US$ 907.3 Mn by the end of 2027.
Global Protein A Resin Market: Drivers
Launch of new products is expected to propel growth of the global protein A resin market over the forecast period. For instance, in March 2020, Avantor, Inc. launched a new recombinant Protein A affinity chromatography resin used to purify antibodies during mAbs production.
Global Protein A Resin Market: Opportunities
Approval and launch of biosimilars is expected to offer lucrative growth opportunities for players in the global protein A resin market. For instance, in May 2018, Pfizer, Inc., a U.S.-based pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for RETACRIT, which is a biosimilar to Epogen and Procrit. It is the first and only FDA approved biosimilar erythropoiesis-stimulating agent.
Global Protein A Resin Market: Restraints
Increasing research on bi-specific antibodies and antibody fragments is expected to hinder growth of the global protein A resin market. In the recent times, bio-pharmaceutical companies are focused on R&D in antibodies fragments and bi-specific antibodies. Furthermore, these antibodies also exhibit promising results in the various therapies such as monoclonal antibodies. However, purification of these antibodies requires protein L instead of protein A, due to lack of fragment crystallisable region.
The global protein A resin market was valued at US$ 474.0 Mn in 2019 and is forecast to reach a value of US$ 907.3 Mn by 2027 at a CAGR of 8.5% between 2020 and 2027. Major factor driving the growth of global protein A resin market during the forecast period include technological advancement, and increasing approvals of monoclonal antibodies.
Natural Protein A held dominant position in the global protein A resin market in 2019, accounting for 63.1% share in terms of value, followed by Recombinant Protein A, respectively.
R&D in rapid prototyping is expected to propel growth of the global protein A resin market over the forecast period. For instance, in June 2020, researchers from Vilnius University, Lithuania, reported employing a single bio-based resin derived from soy beans, suitable for optical 3D printing in the scales from nano- to macro-dimensions, which can be processed even without the addition of photoinitiator.
Major players in the global protein A resin market are focused on investment in expansion of manufacturing capabilities to enhance their market share. For instance, in July 2018, GenScript Biotech Corporation announced to invest US$ 75 million to establish a modern biologics discovery, development, clinical and commercial manufacturing center in the city of Zhenjiang, Jiangsu Province, China.
Global Protein A Resin Market: Competitive Landscape
Major players operating in the global protein A resin market include, GE Healthcare, Thermo Fisher Scientific, Repligen, Tosoh Bioscience, EMD Millipore, Novasep, GenScript Biotech Corporation, Purolite Life Sciences, and Expedeon Ltd.
Global Protein A Resin Market: Key Developments
Major players in the global protein A resin market are focused on investment in expansion of R&D capabilities to expand their product portfolio. For instance, in June 2020, Avantor, Inc. announced the expansion of the company's Bridgewater, N.J. (U.S) innovation center.